---
title: Preoperative chemotherapy, radiotherapy and surgical decision-making in patients
  with borderline resectable and locally advanced pancreatic cancer
date: '2023-11-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38036745/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231201170742&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Surgical resection combined with systemic chemotherapy is the cornerstone
  of treatment for patients with localized pancreatic cancer. Upfront surgery is considered
  suboptimal in cases with extensive vascular involvement, which can be classified
  as either borderline resectable pancreatic cancer or locally advanced pancreatic
  cancer. In these patients, FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy
  is currently used as preoperative chemotherapy and is eventually combined ...
disable_comments: true
---
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases with extensive vascular involvement, which can be classified as either borderline resectable pancreatic cancer or locally advanced pancreatic cancer. In these patients, FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy is currently used as preoperative chemotherapy and is eventually combined ...